Company intelligence / Profile preview

Metagen DX

Tsuruoka-city, Yamagata Prefecture, Japanmetagendx.gr ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

Metagen Therapeutics has established Japan’s first dedicated clinical trial drug production center for FMT products and leverages its proprietary Gut Microbiome Bank as a core resource. The company operates both medical service and drug discovery businesses focused on intestinal microbiome-based therapeutics. Clinical results are not detailed in public sources, but the company is advancing early-stage development of live biotherapeutic products based on fecal microbiota transplantation.

Therapeutic areas: Gastroenterology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Beyond the preview

Go deeper on Metagen DX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metagen DX.

Explore the full profile